DHVI Mission:
The Duke Human Vaccine Institute will develop innovative diagnostics, vaccines  and therapeutics to prevent and treat diseases of global importance, work to implement them to eliminate health disparities, and train the next generation of scientists.

The Duke Human Vaccine Institute (DHVI) has established a place of national and international leadership in the fight against major infectious diseases. DHVI plays an integral leadership role in the Global HIV/AIDS Vaccine Enterprise and is a pioneer in emerging infections and biodefense research. By focusing on the scientific “bottlenecks” for the development of HIV, TB, and other vaccines, DHVI investigators continue to make significant contributions to overcome global health challenges on behalf of society. More

Press Releases

Scanning electron micrograph of HIV particles infecting a human H9 T cell, colorized in blue, turqoise, and yellow. Credit: NIAID

Duke VTEU Names Valley Fever External Advisory Panel
Duke News and Communications
October 27, 2015 

Immune Responses Provide Clues for HIV Vaccine Development
National Institute of Allergy and Infectious Diseases
October 21, 2015

Monkey Model Discovery Could Spur CMV Vaccine Development
Duke News and Communications
October 19, 2015 

Recent Publications

Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodies
Wilton B. Williams, Hua-Xin Liao, M. Anthony Moody, Thomas B. Kepler, S. Munir Alam, Feng Gao, Kevin Wiehe, Ashley M. Trama, Kathryn Jones, Ruijun Zhang, Hongshuo Song, Dawn J. Marshall, John F. Whitesides, Kaitlin Sawatzki, Axin Hua, Pinghuang Liu, Matthew Z. Tay, Kelly Seaton, Xiaoying Shen, Andrew Foulger, Krissey E. Lloyd, Robert Parks, Justin Pollara, Guido Ferrari, Jae-Sung Yu, Nathan Vandergrift, David C. Montefiori, Magdalena E. Sobieszczyk, Scott Hammer, Shelly Karuna, Peter Gilbert, Doug Grove, Nicole Grunenberg, Julie McElrath, John R. Mascola, Richard A. Koup, Lawrence Corey, Gary J. Nabel, Cecilia Morgan, Gavin Churchyard, Janine Maenza, Michael Keefer, Barney S. Graham, Lindsey R. Baden, Georgia D. Tomaras, and Barton F. Haynes Science aab1253Published online 30 July 2015 [DOI:10.1126/science.aab1253]

Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission.
Permar SR, Fong Y, Vandergrift N, Fouda GG, Gilbert P, Parks R, Jaeger FH, Pollara J, Martelli A, Liebl BE, Lloyd K, Yates NL, Overman RG, Shen X, Whitaker K, Chen H, Pritchett J, Solomon E, Friberg E, Marshall DJ, Whitesides JF, Gurley TC, Von Holle T, Martinez DR, Cai F, Kumar A, Xia SM, Lu X, Louzao R, Wilkes S, Datta S, Sarzotti-Kelsoe M, Liao HX, Ferrari G, Alam SM, Montefiori DC, Denny TN, Moody MA, Tomaras GD, Gao F, Haynes BF. J Clin Invest. 2015 Jun 8. pii: 81593. doi: 10.1172/JCI81593.

New approaches to HIV vaccine development.
Haynes BF. Curr Opin Immunol. 2015 Jun 4;35:39-47. doi: 10.1016/j.coi.2015.05.007. Review. PMID: 26056742


Video Presentations

Broadly neutralizing HIV-1 antibody identified in a lupus patient
March 11, 2014
Dr. Barton Haynes, DHVI and Duke CHAVI-ID Director, discusses recent findings from a study led by DHVI investigators in which a broadly neutralizing antibody was identified in a lupus patient who was chronically infected with HIV.